German Chancellor
The U.S. plan would create “severe complications” for the production of vaccines, a German government spokeswoman said Thursday in an email. Without the incentive of profits from research and development spending, drugmakers might not move as aggressively to make vaccines in the future, the industry has argued.
Pharmaceutical stocks that had sunk on the news of the U.S. proposal rebounded on Merkel’s stance.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.